Grant H. Skrepnek, Ph.D., R.Ph.

Professor

Pharmacy Clinical & Admin Sci

Phone (405) 271-6878 x47105

Fax (4050 271-6430

Office CPB 214

Email grant-skrepnek@ouhsc.edu

Summary

I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.


Research

Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.



Publications & Presentations

<< 13 14 15 16 17 18 19 > >>
    76. Gilligan A M, Skrepnek G H. An analysis of security price risk and return among publicly traded pharmacy corporations. Research in social & administrative pharmacy : RSAP. 2013; 9 : 828-40

    77. Barnes C J, Caon C, Foley J F, Friedman M, Menzin J, Nair K V, Nichols C, Olvey E L, Owens G M, Pill M W, Skrepnek G H, White L A, Zerkowski K. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care. Journal of managed care pharmacy : JMCP. 2013; 19 : S1-53

    78. Armstrong E P, Skrepnek G H, Sasane M, Snodgrass S M, Ballas S K. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. Journal of medical economics. 2013; 16 : 10-8

    79. Owens G M, Olvey E L, Skrepnek G H, Pill M W. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. Journal of managed care pharmacy : JMCP. 2013; 19 : S41-53

    80. Amini A, Patanwala A E, Maegawa F B, Skrepnek G H, Jie T, Gruessner R W, Ong E S. Effect of epidural analgesia on postoperative complications following pancreaticoduodenectomy. American journal of surgery. 2012; 204 : 1000-4; discussion 1004-6

<< 13 14 15 16 17 18 19 > >>



Grants

<< 1 2 3 4 >>
    11. Improving the Health of Americans through Prevention and Management of Diabetes, Heart Disease, and Stroke. Non-federal. Start Date: 2019. End Date: 2020.

    12. Allergan (PI: Keast). Federal Non-NIH. Start Date: 2018. End Date: 2019.

    13. Otsuka (Skrepnek/Keast PI). Non-federal. Start Date: 2018. End Date: 2019.

    14. Research Fellowship. PhRMA. Start Date: 2017. End Date: 2018.

    15. Development of a Predictive Model for METAVIR Fibrosis Scores for Patients Chronically Infected with Hepatitis C Virus. Misc Non-Federal. Start Date: 2017.

<< 1 2 3 4 >>



Awards and Honors


no results

Education


no results

Administrative Assignments

                                                
     1. Role: Director. Scope: Department. Date: 2019.
                                                
     2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.